Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
Queensland Health
Cantor Fitzgerald

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,622,441

« Back to Dashboard

Title:Sustained release pharmaceutical compounds to prevent abuse of controlled substances
Abstract: The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes.
Inventor(s): Mickle; Travis (Charlottesville, VA), Krishnan; Suma (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Lauderback; Christopher (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA)
Assignee: Shire LLC (Florence, KY)
Filing Date:Aug 23, 2004
Application Number:10/923,257
Claims:1. A pharmaceutical composition comprising: codeine; and a carrier covalently bound to the codeine in a manner that renders the codeine pharmacologically inactive or provides reduced pharmacological activity compared to codeine alone when administered parenterally, but provides pharmacologically effective amounts of codeine when administered orally; wherein the carrier is a peptide selected from the group consisting of Gly-Gly-Leu, Gly-Gly-Glu, Gly-Gly-Ile, Gly-Gly-Phe, Gly-Leu-Ile, Gly-Phe-Ile, Gly-Leu-Leu, Gly-Phe-Leu, Leu-Pro-Glu, Leu-Pro-Leu, Leu-Pro-Phe, Pro-Pro-Glu, Pro-Pro-Leu, Pro-Pro-Ile, Pro-Pro-Phe, Glu-Glu-Glu, Leu-Leu-Glu, Leu-Leu-Leu, Gly.sub.4-Leu (SEQ ID NO: 1), Glu.sub.5 (SEQ ID NO: 2), Gly.sub.4-Ile (SEQ ID NO: 3), Gly.sub.4-Phe (SEQ ID NO: 5), Glu.sub.2-Gly.sub.2 (SEQ ID NO: 6), Glu.sub.2-Gly.sub.2-Leu (SEQ ID NO: 8), or Glu2-Gly2-Ile (SEQ ID NO: 9); wherein the hydroxyl group of codeine is bound to the C-terminus of the carrier.

2. The composition of claim 1, wherein said composition is in tablet, a capsule, an oral suspension or an oral solution.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Queensland Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.